Protalix Biotherapeutics, Inc. (PLX) Completes Phase III Trial for Gaucher Disease Treatment

By Jonathan
15 September 2009 @ 04:25 am EDT

Protalix Biotherapeutics, Inc. continues to make headlines with its innovative compound, a recombinant form of glucocerebrosidase (prGCD). Last week, the company released that its compound had received the FDA’s Orphan Drug Donation. Yesterday, the company announced that they have completed the Phase III trial for prGCD. The compound is designed to treat Gaucher disease, a rare and serious lysosomal storage disorder in humans with debilitating symptoms.

Small Cap News in collaboration with Quality Stocks

E-Newsletters

We value your privacy. Your email address will not be shared.